-
Nilotinib, sold
under the
brand name
Tasigna among others, is a anti-cancer
medication used to
treat chronic myelogenous leukemia (CML)
which has the...
-
these changes resulted in the
discovery of
nilotinib.
Nilotinib is a
selective Bcr-Abl
kinase inhibitor.
Nilotinib is 10-30 fold more
potent than imatinib...
- of imatinib. A
second TK inhibitor,
nilotinib, was
approved by the FDA for the same indication. In 2010,
nilotinib and
dasatinib were also
approved for...
-
currently available inhibitors to
treat CML are imatinib, dasatinib,
nilotinib,
bosutinib and ponatinib.
Gastrointestinal stromal tumors (GIST) are known...
- journal). ALL and CML
therapies have
targeted JAK2 as well as BCR-ABL
using nilotinib and
ruxolitinib within murine models to
downregulate downstream cytokine...
- This is a list of
adverse effects of the anti-cancer drug
nilotinib,
sorted by
frequency of occurrence. Very
common (>10% incidence)
adverse effects include:...
- sirolimus, alefacept, and the
tyrosine kinase inhibitors, imatinib,
nilotinib, and dasatinib.
Experimental therapies under investigation include endothelin...
-
Sorafenib (Nexavar)
Sunitinib (Sutent)
Dasatinib (Sprycel)
Lapatinib (Tykerb)
Nilotinib (Tasigna)
Bosutinib (Bosulif)
Ponatinib (Iclusig)
Asciminib (Scemblix)...
- investigator-selected
tyrosine kinase inhibitors (IS-TKIs) (imatinib,
nilotinib, dasatinib, or bosutinib). The main
efficacy outcome measure was major...
-
Approval of
Dasatinib and
Nilotinib for
Resistant Leukemia MD
Anderson researchers demonstrate the
efficacy of
dasatinib and
nilotinib,
leading to FDA approval...
